XGene FDA Enforcement & GMP Intelligence™

Inside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will Accept

Revisiting the 2019 PharMEDium Services consent decree as a teaching case: the clearest available precedent for how a 503B outsourcing facility’s aseptic processing failures escalate to FDA’s most severe civil enforcement tool short of seizure.

Inside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will Accept Read More »

Zenzi Pharmaceutical Industries Faces FDA and EMA Simultaneously: What the Dual Enforcement Action Reveals About Global CGMP Standards and Your Supply Chain Risk

Two regulators on two continents — FDA and Malta’s competent authority within the EMA network — independently reached adverse findings against the same Indian contract manufacturing site, more than a year apart.

Zenzi Pharmaceutical Industries Faces FDA and EMA Simultaneously: What the Dual Enforcement Action Reveals About Global CGMP Standards and Your Supply Chain Risk Read More »

Babikian Healthcare Products Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Dietary Supplement and OTC Drug Sites Must Know

FDA added Babikian Healthcare Products to Import Alert 66-40 with a blanket Detention Without Physical Examination across its entire drug product line — with no companion Warning Letter publicly available to explain the underlying finding.

Babikian Healthcare Products Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Dietary Supplement and OTC Drug Sites Must Know Read More »

CareFusion 213, LLC (BD) Class I Recall — ChloraPrep Sterile Antiseptic Applicators: The Sterile Manufacturing System Failure Behind the Recall and What Every Aseptic Processing Director Must Address

A Class I recall of BD ChloraPrep sterile antiseptic applicators for non-sterility and a packaging-seal defect follows an April 2026 Warning Letter at the same El Paso, TX facility citing the identical failure pair.

CareFusion 213, LLC (BD) Class I Recall — ChloraPrep Sterile Antiseptic Applicators: The Sterile Manufacturing System Failure Behind the Recall and What Every Aseptic Processing Director Must Address Read More »

01 Article Cover Alcoa Data Completeness Deletion Risk 1024x576

ALCOA+ Data Completeness — The Deletion Problem FDA Finds First

FDA investigators are trained to look for what is missing from your data records before they look at what is present — and the deletion of failed runs, rejected results, or inconvenient data points is the data integrity violation that most reliably transforms a 483 observation into a Warning Letter. That sentence reflects one of

ALCOA+ Data Completeness — The Deletion Problem FDA Finds First Read More »